Vibe Bio
resources
Case study: Orphan Therapeutics
How Orphan Therapeutics Accelerator Is Optimizing Rare Disease Search & Eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
Webinar: Watch on-demand
The AI buying guide for BD&L executives
The AI buying guide for Business Development & Licensing (BD&L) executives Webinar on-demand Evaluate & choose AI solutions to achieve real results Your biopharma BD&L teams are under unprecedented pressure…
Additional resources
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
4 major disruptions to the hunt for new cures, and how AI can help
The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and…
No posts
No posts
No posts
No posts
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.